Skip to main content
. 2017 Jun 6;8:646. doi: 10.3389/fimmu.2017.00646

Figure 3.

Figure 3

Increased CDC of rituximab-derived immunoglobulin gamma 1 (IgG1) and IgG3 but not IgG2 and IgG4 upon Fc-galactosylation. Complement-dependent lysis of CD20+ target cells in the presence of galactosylated or degalactosylated human anti-CD20 IgG isotypes. Exemplary lysis curves and EC50 values of three independent experiments are shown. Statistical analysis: paired two-tailed Student’s t-test *p < 0.05, **p < 0.01.

HHS Vulnerability Disclosure